Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio

WINDTREE THERAPEUTICS INC /DE/

Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.
Company cites positive Phase 2b SEISMiC study in early cardiogenic shock as catalyst for potential non-dilutive partnership.
Existing Lee's Pharmaceuticals deal offers up to $138M in milestones plus low double-digit royalties for Greater China.
NGA has advised on transactions with aggregate value approaching $400M from 2023 through 2024.
Proceeds from any deal would support advancement of Windtree's novel preclinical oncology platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.